ID   MM1.R
AC   CVCL_8794
SY   MM1.r; MM.1R; MM1-R; MM-1R; MM1R; MM1.R(L); MM1.RL
DR   BTO; BTO:0003929
DR   ATCC; CRL-2975
DR   CCRID; 3101HUMSCSP5050
DR   Cell_Model_Passport; SIDM01264
DR   Cosmic; 1424219
DR   Cosmic; 2081429
DR   GEO; GSM1374684
DR   IZSLER; BS TCL 235
DR   Wikidata; Q54906036
RX   CelloPub=CLPUB00604;
RX   PubMed=12691914;
RX   PubMed=17692805;
RX   PubMed=28196595;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   Characteristics: Produces IgA lambda (ATCC=CRL-2975).
CC   Characteristics: Resistant to dexamethasone.
CC   Doubling time: ~72 hours (ATCC=CRL-2975).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Val536_Asn545delValPheValAlaGlnThrValLeuGluAsninsAsp (c.1604-1630delTCTTTGTGGCCCAAACTGTTCTAGAAA); Zygosity=Homozygous (PubMed=17692805).
CC   Omics: Array-based CGH.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC=CRL-2975; Technion Genomics Center BCF
ST   Amelogenin: X
ST   CSF1PO: 9,14
ST   D10S1248: 12,15
ST   D12S391: 17,24
ST   D13S317: 13
ST   D16S539: 12
ST   D18S51: 11,16
ST   D19S433: 13
ST   D1S1656: 11,12
ST   D21S11: 29,30
ST   D22S1045: 10,11
ST   D2S1338: 21,22
ST   D2S441: 11
ST   D3S1358: 16,17
ST   D5S818: 8,12
ST   D7S820: 10,11
ST   D8S1179: 14
ST   FGA: 20,24
ST   Penta D: 2.2,9
ST   Penta E: 13,15
ST   TH01: 7,8
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5801 ! MM.1
SX   Female
AG   45Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 21
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   PubMed=12691914; DOI=10.1016/S0301-472X(03)00023-7;
RA   Greenstein S., Krett N.L., Kurosawa Y., Ma C.-G., Chauhan D.,
RA   Hideshima T., Anderson K.C., Rosen S.T.;
RT   "Characterization of the MM.1 human multiple myeloma (MM) cell lines:
RT   a model system to elucidate the characteristics, behavior, and
RT   signaling of steroid-sensitive and -resistant MM cells.";
RL   Exp. Hematol. 31:271-282(2003).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//